UBC The current public health crisis has accelerated collecting data in a decentralized manner. The biopharmacuetical industry had already begun to harness transformative approaches to collecting data in novel ways, including from remote sources across a wide range of settings and using diverse modalities. The pandemic has proven to be a catalyst for an even more comprehensive set of solutions to collect critical evidence beyond the walls of the traditional study setting. Regulatory agencies propelled this trend by releasing new guidances.